Novel lipid-regulating drugs

Expert Opinion on Investigational Drugs

Volumn 9, Issue 11, 2000, Pages 2619-2628

  Thompson, G R ^a   Naoumova, R P ^a  

^a MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

Author keywords

ACAT inhibitors; Bile acid sequestrant; CETP inhibitor; Cholesterol absorption inhibitor; HMG CoA reductase inhibitor; Nicotinic acid

Indexed keywords

1,4 BIS(4 METHOXYPHENYL) 3 (3 PHENYLPROPYL) 2 AZETIDINONE; 2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ABC TRANSPORTER; ANTILIPEMIC AGENT; AVASIMIBE; AZETIDINONE DERIVATIVE; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN; COLESEVELAM; COLESTILAN; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NICOTINIC ACID; PITAVASTATIN; PLACEBO; POLYAMINE DERIVATIVE; PROTEIN INHIBITOR; ROSUVASTATIN; SCAVENGER RECEPTOR; SCH 46461; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHOLESTEROL TRANSPORT; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; LIPID ABSORPTION; LIPID METABOLISM; MACROPHAGE; MONOCYTE; NONHUMAN; RASH; REVIEW; TURNOVER TIME;

EID: 0033757009     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.11.2619     Document Type: Review

References (35)

1. New prospects for lipid-lowering drugs
2. Prevention of coronary heart disease in clinical practice: Recommendations of the second joint task force of European and other societies on coronary prevention
3. Joint British recommendations on prevention of coronary heart disease in clinical practice
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S)
9. Clinical lipidology at the end of the millenium
10. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial
11. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the scandinavian simvastatin survival study
12. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol
13. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia
14. Colestilan: A new bile acids sequestrant resin. A review of its clinical study in hypercholesterolaemia in Japan
15. Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in Type II hyperlipoproteinemia
16. Colesevelam hydrochloride (cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastro-intestinal side effects
17. Fluvastatin extended-release formulation is effective in treating primary hypercholesterolaemia
18. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low density lipoprotein cholesterol in heterozygous familial hypercholesterolemia
19. Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolaemia
20. The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine and circulates enterohepatically
21. Low-density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of intestinal cholesterol absorption in 243 hypercholesterolemic subjects: Results of a dose-response study
22. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
23. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype
24. Poor responders to statins: A potential target for stanol esters
25. Cholesterol-lowering effect of N-(alpha-methylbenzyl) linoleamide (Melinamide) in cholesterol-fed diabetic rats
26. Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: Effect of dietary fat and cholesterol
27. The ACAT inhibitor Avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits
28. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs
29. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
30. Peroxisome proliferator-activated receptor ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
31. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits
32. The 'best' of cholesterols, the 'worst' of cholesterols: A tale of two receptors
33. Gene transfer and hepatic overexpression of the HDL receptor SR-B1 reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse
34. The ABCs of cholesterol efflux
35. Regulation of absorption and ABC 1-mediated efflux of cholesterol by RXR heterodimers